Overexpression and/or overactivation of
sphingosine kinase 1/2 (SphK1/2) is important for
tumorigenesis and progression of
cervical cancer. The current study examined the potential activity and signaling mechanisms of SKI-V, a non-
lipid small molecule SphK inhibitor, against
cervical cancer cells. In different primary and immortalized
cervical cancer cells, SKI-V exerted significant anti-
cancer activity by inhibiting cell viability, colony formation, proliferation, cell cycle progression and cell migration. Significant apoptosis activation was detected in SKI-V-treated
cervical cancer cells. Significantly, SKI-V also provoked programmed
necrosis cascade in
cervical cancer cells, as it induced mitochondrial p53-cyclophilin-D-adenine
nucleotide translocator-1 (ANT1) complexation, mitochondrial membrane potential collapse,
reactive oxygen species production and the release of
lactate dehydrogenase into the medium. Further, SKI-V blocked SphK activation and induced
ceramide accumulation in primary
cervical cancer cells, without affecting SphK1/2 expression. SKI-V-induced cytotoxicity in
cervical cancer cells was largely inhibited by
sphingosine-1-phosphate or the SphK1 activator K6PC-5, but was sensitized by adding the short-chain
ceramide C6. Moreover, SKI-V inhibited Akt-mTOR (
mammalian target of rapamycin) activation in primary
cervical cancer cells, and its cytotoxicity was mitigated by a constitutively-active Akt. In vivo, daily
intraperitoneal injection of SKI-V significantly inhibited subcutaneous primary
cervical cancer xenograft growth in nude mice. Together, the SphK inhibitor SKI-V suppresses
cervical cancer growth in vitro and in vivo.